Why IMU is a multi multi bagger, page-26161

Rainman,

It sounds like the best option is for you to sell up and move on !

As you said “very successful interim results”

So it’s probably time for you to listen to the market and ignore the science.

And take note that the non-existent biotech institutional investors are staying away in droves because these institutions that don’t exist also don’t trust PH.

I imagine you are aware the institutional investors are really struggling ATM because new funds and existing funds are drying up. Index Investing has taken over as the preferred place for small investors to place their money.

So just maybe it will require a deal to get the SP moving again.

In the meantime the science is progressing and in the case of Azer-Cel it’s very obvious that LC is following the path laid down by Keytruda. Get the first indication approved by the FDA then branch out to include the other blood cancers that express CD19.

So the market for Azer-Cel will be much bigger than $2.5bn. Probably >$10bn. This fact won’t be lost on experts who monitor the progress of small caps like IMU.

At this point in time the divergence between the value of the IP and the SP has never been greater. If in the next 10 weeks IMU deliver good results for Vaxinia , Bilary Cancer and ONCARLYTICS that divergence could magnify greatly , as this market isn’t interested in looking at it.

It’s that divergence is where the money is. That’s the mispricing of the shares.

If you don’t see that or disagree then it’s a good time to sell and move on